(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 1.64% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Novartis Ag's revenue in 2024 is $49,924,000,000.On average, 4 Wall Street analysts forecast NVS's revenue for 2024 to be $98,512,083,108,000, with the lowest NVS revenue forecast at $96,390,944,480,000, and the highest NVS revenue forecast at $102,233,431,961,200. On average, 4 Wall Street analysts forecast NVS's revenue for 2025 to be $103,657,349,586,000, with the lowest NVS revenue forecast at $100,646,810,800,000, and the highest NVS revenue forecast at $109,943,689,360,000.
In 2026, NVS is forecast to generate $106,601,432,544,000 in revenue, with the lowest revenue forecast at $104,601,248,828,000 and the highest revenue forecast at $112,318,190,577,200.